Gonorrhea Therapeutics Market

Gonorrhea Therapeutics Market (Gonococcal Infection: Uncomplicated Gonococcal Infection, Gonococcal Arthritis, Gonococcal Meningitis, and Endocarditis; Treatment: Monotherapy and Dual Therapy; Route of Administration: Oral and Injectable; Gender: Women and Men; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Gonorrhea Therapeutics Market - High Scope of Advancement with Curative Approach

Improved sensitivity of early diagnostic screening tools has highlighted grave concerns regarding the surge in gonorrhea incidences. As per a survey conducted by the Centers for Disease Control and Prevention, 555,608 cases of gonorrhea were reported in 2017, in the U.S., demonstrating an increase of 18.6% from 2009. These figures have hard-pressed the governments of numerous countries to take preventive and curative measures for relegating the prevalence of gonorrhea.

According to the gonorrhea therapeutics market research report published by Transparency Market Research (TMR), women are more susceptible to this disease than men, and the number of women availing therapeutics is on an exponential increase, thereby making women the key demographic of the market. The scramble of market players towards addressing the issue at the grass-root level has engendered several vaccines, including 4CMenB and rLP2086, which harbingers steady growth prospects for the landscape. However, literatures claiming the progressive resistance of gonorrhea to therapeutics could surface uncertainties regarding market advancement.

gonorrhea therapeutics market infographic

To know the scope of our report Get a Sample on Gonorrhea Therapeutics Market

'Women More Susceptible to Gonorrhea than Men', finds TMR Study

The connection of gonorrhea with infertility has accelerated the pace of research & development activities among market players to introduce effective therapeutics to combat this public health threat. A research team at the Louisiana State University Health Sciences discovered a novel antibiotic - zoliflodacin - to inhibit bacteria’s DNA synthesis with a differentiated approach than current antibiotics, which was well-received by the FDA, and the same has been marketed as an oral treatment for gonorrhea. Besides oral drugs, medical personnel recommend dual therapy over monotherapy, given the growing resistance of Neisseria Gonorrhoeae to antibiotics.

A majority of women with gonorrhea show subtle signs of ongoing damage to the uterine tract, which, if left untreated, could cause involuntary infertility, ectopic pregnancy, or even chronic pelvic pain. As a result, this TMR study identifies that, the number of women availing gonorrhea therapeutics is projected to rise at a CAGR of ~6% during 2019-2027, with uncomplicated gonococcal infection being the leading cause.

Get a glimpse of the in-depth analysis through our Report Brochure

Why Partnerships with Hospital Pharmacies Could be Profitable

The sales of gonorrhea therapeutics are projected to witness significant uptake from hospital pharmacies, as hospitals remain preferred care centers for patients diagnosed with gonorrhea. According to TMR’s estimates, hospital pharmacies will account for a value tantamount to ~US$ 548 Mn in 2019, out of which, ~37% of sales will come from hospital pharmacies based in North America alone.

Propitious environment for the growth of the healthcare sector in North America that is attributable to the intervention of the government in creating awareness regarding the prevalence of diseases, and hefty financial allocations for R&D activities are also likely to reflect on the advancement of the gonorrhea therapeutics market. Currently, North America monopolizes the gonorrhea therapeutics market; however, the Asia Pacific market holds profitable prospects on account of the growing sprawl of bacterial infections. On top of it, improvements in healthcare infrastructure coupled with financial lucidity of individuals has encouraged a large base to opt for effective gonorrhea therapeutics.

gonorrhea therapeutics market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

Authors of the report opine that, the gonorrhea therapeutics market will rise from ~US$ 1.4 Bn in 2019 to ~US$ 2 Bn in 2027, representing a CAGR of ~5% during the forecast period, with the shifting paradigm from a preventive to curative healthcare approach. A heated competitive landscape in the global pharmaceutical vicinity is encouraging market players to penetrate into new markets to channelize the supply of therapeutics and consolidate their market position.

However, the same is not achieved only by forward integration but also by inorganic practices such as acquisitions, mergers, and collaborations, in order to establish distribution partnerships with regional and local players. For instance, AstraZeneca announced the acquisition of Takeda Pharmaceutical Company Limited to expand in regions with high growth potential. To add to that, market players can prioritize investments towards the development of vaccines to infiltrate into the market with a curative approach

Gonorrhea Therapeutics Market: Overview

  • The global gonorrhea therapeutics market is projected to be valued at ~US$ 1.4 Bn in 2019, and expand at a CAGR of ~5.3% from 2019 to 2027. The rising prevalence of the disease and increasing use of new diagnostic tests are key factors that fuel the global gonorrhea therapeutics market.
  • Gonorrhea is a sexually transmitted infection caused by a bacterium, and can be transmitted through sexual contact. All people who are sexually active may be at the risk of acquiring gonorrhea. Gonorrhea can infect the urethra (the tube that allows urine and semen to pass out of the body), cervix, rectum, throat, mouth, and eyes. Though, several people suffering from gonorrhea do not exhibit any symptoms.
  • If symptoms do occur, they usually appear one to seven days after an infection. Symptoms can include vaginal pain, painful urination, and an abnormal discharge from the vagina, urethra, or rectum. Gonorrhea tests include obtaining samples from the sites of suspected infection and testing for the presence of the bacteria.
  • Gonorrhea can be treated and cured using antibiotics; however, some strains of gonorrhea have become resistant to a few antibiotics. Gonorrhea can increase the risk of the sexual transmission of HIV.
  • Gonorrhea can be transmitted through sexual intercourse. Transmission occurs when secretions from infected mucous membranes or semen of a person with a urethral infection come into contact with the mucous membranes of another person. Condom-less penetrative vaginal sex and anal sex are significantly high risk behaviors for the transmission of gonorrhea. Gonorrhea can be transmitted when a person who has an infection in the mouth or throat performs oral sex on another person, or when a person performs oral sex on a person who has a genital infection.

Global Gonorrhea Therapeutics Market: Drivers & Restraints

  • Rising Prevalence of Gonorrhea: Gonorrhea is the second-most commonly reported notifiable disease in the U.S. Infections due to Neisseria gonorrhea, such as those resulting from Chlamydia trachomatis, are a major cause of pelvic inflammatory disease (PID) in the U.S. Moreover, epidemiologic and biologic studies provide evidence that gonococcal infections facilitate the transmission of HIV infection.
  • Emergence of Antibiotic-Resistant Gonococcal Strain: CDC data highlights the rising resistance to one of the two antibiotics in the dual therapy for gonorrhea, a development that threatens the last remaining effective treatment for the disease. N. gonorrhea has progressively developed resistance to each of the antimicrobials used for the treatment of gonorrhea. Declining susceptibility to cefixime resulted in a change to the CDC treatment guidelines in 2015, so that dual therapy with ceftriaxone and azithromycin is presently the only CDC recommended treatment regimen for gonorrhea.

Global Gonorrhea Therapeutics Market: Segment Analysis

  • The global gonorrhea therapeutics market has been segmented based on gonococcal infection, treatment, route of administration, gender, distribution channel and region
  • In terms of gonococcal infection, the global gonorrhea therapeutics market has been classified into uncomplicated gonococcal infection, gonococcal arthritis, gonococcal meningitis, and endocarditis. In terms of treatment, the global gonorrhea therapeutics market has been classified into monotherapy and dual therapy. In terms of route of administration, the global gonorrhea therapeutics market has been classified into oral and injectable. In terms of gender, the global gonorrhea therapeutics market has been bifurcated into women and men.
  • The uncomplicated gonococcal infection segment is projected to dominate the gonorrhea therapeutics market by the end of 2019. It is projected to maintain its dominance during the forecast period too.
  • Based on distribution channel, the global gonorrhea therapeutics market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment is estimated to dominate the gonorrhea therapeutics market by the end of 2019.

Global Gonorrhea Therapeutics Market: Regional Segmentation

  • In terms of region, the global gonorrhea therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America
    • North America dominated the global gonorrhea therapeutics market in 2018 due to the growing prevalence of STDs and rapid advances in healthcare infrastructure in the region.
    • According to a recent study by the World Health Organization, in the U.S. alone, ~1 million cases of gonorrhea are reported annually. Favorable reimbursement policies and government funding to numerous health organizations for the development of drug-resistant gonorrhea treatment are projected to remain the key drivers of the gonorrhea therapeutics market in the region.
  • Europe
    • The gonorrhea therapeutics market in Europe is anticipated to expand at a considerable growth rate in the near future, owing to the increasing incidence of gonococcal infection in the region. Gonorrhea is the second-most notified sexually transmitted infection in Europe, after chlamydia.
  • Asia Pacific
    • The gonorrhea therapeutics market in Asia Pacific is projected to expand at a notable CAGR during the forecast period, due to a large patient pool and rise in investments in healthcare in countries such as China in the region.

Global Gonorrhea Therapeutics Market: Major Players

  • Key players operating in the global gonorrhea therapeutics market include
    • GlaxoSmithKline plc.
    • Merck & Co., Inc.
    • Pfizer Inc
    • AstraZeneca
    • Hologic, Inc.
    • Danaher
    • Abbott
    • Becton Dickinson and Company
    • F. Hoffmann-La Roche Ltd.
  • These players are adopting strategies such as new product development, partnerships, and acquisitions to remain competitive in the global gonorrhea therapeutics market.

Gonorrhea Therapeutics Market - Segmentation

In order to present an incisive view of the gonorrhea therapeutics market, analysts and researchers of the report have segregated the gonorrhea therapeutics market based on the gonococcal infection, treatment, route of administration, gender, distribution channel, and region. This comprehensive business study also analyzes the incremental opportunity present in the gonorrhea therapeutics market during the forecast period. The key segments of the gonorrhea therapeutics market are as mentioned below:

Gonococcal Infection

  • Uncomplicated Gonococcal Infection
  • Gonococcal Arthritis
  • Gonococcal Meningitis and Endocarditis

Treatment

  • Monotherapy
  • Dual Therapy

Route of Administration

  • Oral
  • Injectable

Gender

  • Women
  • Men

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of gonorrhea therapeutics market?

Gonorrhea therapeutics market to reach a valuation of ~US$ 2 Bn by 2027

What is the anticipated CAGR of the gonorrhea therapeutics market in the forecast period?

Gonorrhea therapeutics market to expand at a CAGR of ~5.3% from 2019 to 2027

What are the key driving factors for the growth of the gonorrhea therapeutics market?

Gonorrhea therapeutics market is driven by rising prevalence of gonorrhea and use of new diagnostic tests

Which region is expected to project the highest market share in the global gonorrhea therapeutics market?

North America accounted for a major share of the global gonorrhea therapeutics market

Who are the key players in the gonorrhea therapeutics market?

Key players in the global gonorrhea therapeutics market include GlaxoSmithKline plc. Merck & Co., Inc., Pfizer Inc, AstraZeneca, Hologic, Inc., Danaher

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Gonorrhea Therapeutics Market 

    4. Market Overview

        4.1. Introduction

            4.1.1. Gonococcal Infection Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Gonorrhea Therapeutics Market Analysis and Forecast, 2017–2027

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Market Outlook

        5.1. Regulatory Scenario by Region/globally

        5.2. Reimbursement Scenario by Region/globally

    6. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Gonococcal Infection Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Global Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

            6.3.1. Uncomplicated Gonococcal Infection

            6.3.2. Gonococcal Arthritis

            6.3.3. Gonococcal Meningitis and Endocarditis

        6.4. Global Gonorrhea Therapeutics Market Attractiveness, by Gonococcal Infection Type

    7. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Treatment

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Global Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

            7.3.1. Monotherapy

            7.3.2. Dual Therapy

        7.4. Global Gonorrhea Therapeutics Market Attractiveness, by Treatment

    8. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Route of Administration

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Global Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

            8.3.1. Oral

            8.3.2. Injectable

        8.4. Global Gonorrhea Therapeutics Market Attractiveness, by Route of Administration

    9. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Gender

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Global Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

            9.3.1. Women

            9.3.2. Men

        9.4. Global Gonorrhea Therapeutics Market Attractiveness, by Gender

    10.  Global Gonorrhea Therapeutics Market Analysis and Forecast, by Distribution Channel

        10.1. Introduction & Definition

        10.2. Key Findings / Developments

        10.3. Global Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. Online Pharmacies

            10.3.4. Others

        10.4. Global Gonorrhea Therapeutics Market Attractiveness, by Distribution Channel

    11. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Region

        11.1. Key Findings

        11.2. Global Gonorrhea Therapeutics Market Forecast, by Region

            11.2.1. North America

            11.2.2. Europe

            11.2.3. Asia Pacific 

            11.2.4. Latin America

            11.2.5. Middle East & Africa

        11.3. Global Gonorrhea Therapeutics Market Attractiveness, by Region

    12. North America Gonorrhea Therapeutics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. North America Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

            12.2.1. Uncomplicated Gonococcal Infection

            12.2.2. Gonococcal Arthritis

            12.2.3. Gonococcal Meningitis and Endocarditis

        12.3. North America Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

            12.3.1. Monotherapy

            12.3.2. Dual Therapy

        12.4. North America Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

            12.4.1. Oral

            12.4.2. Injectable

        12.5. North America Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

            12.5.1. Women

            12.5.2. Men

        12.6. North America Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

            12.6.1. Hospital Pharmacies

            12.6.2. Retail Pharmacies

            12.6.3. Online Pharmacies

            12.6.4. Others

        12.7. North America Gonorrhea Therapeutics Market Forecast, by Country, 2017–2027

            12.7.1. U.S.

            12.7.2. Canada

        12.8. North America Gonorrhea Therapeutics Market Attractiveness Analysis 

            12.8.1. By Gonococcal Infection Type

            12.8.2. By Treatment 

            12.8.3. By Route of Administration

            12.8.4. By Gender

            12.8.5. By Distribution Channel

            12.8.6. By Country

    13. Europe Gonorrhea Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Europe Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

            13.2.1. Uncomplicated Gonococcal Infection

            13.2.2. Gonococcal Arthritis

            13.2.3. Gonococcal Meningitis and Endocarditis

        13.3. Europe Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

            13.3.1. Monotherapy

            13.3.2. Dual Therapy

        13.4. Europe Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

            13.4.1. Oral

            13.4.2. Injectable

        13.5. Europe Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

            13.5.1. Women

            13.5.2. Men

        13.6. Europe Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

            13.6.1. Hospital Pharmacies

            13.6.2. Retail Pharmacies

            13.6.3. Online Pharmacies

            13.6.4. Others

        13.7. Europe Gonorrhea Therapeutics Market Forecast, by Country/Sub-region, 2017–2027

            13.7.1. Germany

            13.7.2. U.K.

            13.7.3. France

            13.7.4. Spain

            13.7.5. Italy

            13.7.6. Rest of Europe

        13.8. Europe Gonorrhea Therapeutics Market Attractiveness Analysis 

            13.8.1. By Gonococcal Infection Type

            13.8.2. By Treatment 

            13.8.3. By Route of Administration

            13.8.4. By Gender

            13.8.5. By Distribution Channel

            13.8.6. By Country

    14. Asia Pacific Gonorrhea Therapeutics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

            14.2.1. Uncomplicated Gonococcal Infection

            14.2.2. Gonococcal Arthritis

            14.2.3. Gonococcal Meningitis and Endocarditis

        14.3. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

            14.3.1. Monotherapy

            14.3.2. Dual Therapy

        14.4. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

            14.4.1. Oral

            14.4.2. Injectable

        14.5. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

            14.5.1. Women

            14.5.2. Men

        14.6. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

            14.6.1. Hospital Pharmacies

            14.6.2. Retail Pharmacies

            14.6.3. Online Pharmacies

            14.6.4. Others

        14.7. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Country/Sub-region, 2017–2027

            14.7.1. China

            14.7.2. Japan

            14.7.3. India

            14.7.4. Australia & New Zealand

            14.7.5. Rest of Asia Pacific

        14.8. Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis 

            14.8.1. By Gonococcal Infection Type

            14.8.2. By Treatment 

            14.8.3. By Route of Administration

            14.8.4. By Gender

            14.8.5. By Distribution Channel

            14.8.6. By Country/Sub-region

    15. Latin America Gonorrhea Therapeutics Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Latin America Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

            15.2.1. Uncomplicated Gonococcal Infection

            15.2.2. Gonococcal Arthritis

            15.2.3. Gonococcal Meningitis and Endocarditis

        15.3. Latin America Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

            15.3.1. Monotherapy

            15.3.2. Dual Therapy

        15.4. Latin America Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

            15.4.1. Oral

            15.4.2. Injectable

        15.5. Latin America Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

            15.5.1. Women

            15.5.2. Men

        15.6. Latin America Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

            15.6.1. Hospital Pharmacies

            15.6.2. Retail Pharmacies

            15.6.3. Online Pharmacies

            15.6.4. Others

        15.7. Latin America Gonorrhea Therapeutics Market Forecast, by Country/Sub-region, 2017–2027

            15.7.1. Brazil

            15.7.2. Mexico

            15.7.3. Rest of Latin America

        15.8. Latin America Gonorrhea Therapeutics Market Attractiveness Analysis 

            15.8.1. By Gonococcal Infection Type

            15.8.2. By Treatment 

            15.8.3. By Route of Administration

            15.8.4. By Gender

            15.8.5. By Distribution Channel

            15.8.6. By Country/Sub-region

    16. Middle East & Africa Gonorrhea Therapeutics Market Analysis and Forecast

        16.1. Introduction

            16.1.1. Key Findings

        16.2. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

            16.2.1. Uncomplicated Gonococcal Infection

            16.2.2. Gonococcal Arthritis

            16.2.3. Gonococcal Meningitis and Endocarditis

        16.3. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

            16.3.1. . Monotherapy

            16.3.2. Dual Therapy

        16.4. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

            16.4.1. Oral

            16.4.2. Injectable

        16.5. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

            16.5.1. Women

            16.5.2. Men

        16.6. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

            16.6.1. Hospital Pharmacies

            16.6.2. Retail Pharmacies

            16.6.3. Online Pharmacies

            16.6.4. Others

        16.7. Middle East & Africa Gonorrhea Therapeutics Market Forecast by Country/Sub-region, 2017–2027

            16.7.1. GCC Countries

            16.7.2. South Africa

            16.7.3. Israel

            16.7.4. Rest of Middle East & Africa

        16.8. Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis 

            16.8.1. By Gonococcal Infection Type

            16.8.2. By Treatment 

            16.8.3. By Route of Administration

            16.8.4. By Gender

            16.8.5. By Distribution Channel

            16.8.6. By Country/Sub-region

    17. Competition Landscape

        17.1. Market Player – Competition Matrix (by Tier and Size of companies)

        17.2. Market Share Analysis by Company (2018)

        17.3. Company Profiles

            17.3.1. GlaxoSmithKline plc. 

                      17.3.1.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                      17.3.1.2 Financial Overview

                      17.3.1.3 SWOT Analysis

                      17.3.1.4 Strategic Overview

            17.3.2. Merck & Co., Inc.

                      17.3.2.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                      17.3.2.2 Financial Overview

                      17.3.2.3 SWOT Analysis

                      17.3.2.4 Strategic Overview

            17.3.3. Pfizer Inc.

                      17.3.3.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                      17.3.3.2 Financial Overview

                      17.3.3.3 SWOT Analysis

                      17.3.3.4 Strategic Overview

            17.3.4. AstraZeneca 

                      17.3.4.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                      17.3.4.2 Financial Overview

                      17.3.4.3 SWOT Analysis

                      17.3.4.4 Strategic Overview

            17.3.5. Hologic, Inc. 

                      17.3.5.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                      17.3.5.2 Financial Overview

                      17.3.5.3 SWOT Analysis

                      17.3.5.4 Strategic Overview

            17.3.6. Danaher

                      17.3.6.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                      17.3.6.2 Financial Overview

                      17.3.6.3 SWOT Analysis

                      17.3.6.4 Strategic Overview

            17.3.7. Abbott

                      17.3.7.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                      17.3.7.2 Financial Overview

                      17.3.7.3 SWOT Analysis

                      17.3.7.4 Strategic Overview

            17.3.8. Becton Dickinson and Company

                      17.3.8.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                      17.3.8.2 Financial Overview

                      17.3.8.3 SWOT Analysis

                      17.3.8.4 Strategic Overview

            17.3.9. F. Hoffmann-La Roche Ltd

                      17.3.9.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                      17.3.9.2 Financial Overview

                      17.3.9.3 SWOT Analysis

                      17.3.9.4 Strategic Overview

            17.3.10. Other Prominent Key Players

    *Note: Financial details for companies that do not report this information in public domain might not be captured.

    List of Tables

    Table 1: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
    Table 2: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
    Table 3: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 4: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 5: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 6: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
    Table 7: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
    Table 8: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 9: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 10: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 11: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
    Table 12: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
    Table 13: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 14: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 15: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 16: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
    Table 17: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
    Table 18: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 19: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 20: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 21: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
    Table 22: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
    Table 23: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 24: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 25: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 26: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
    Table 27: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
    Table 28: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 29: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 30: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    List of Figures 

     

    Figure 1: Market Size, by Test Type (US$ Mn), 2018

    Figure 2: Market Share, Top Trends, by Product Type

    Figure 3: Global Gonorrhea Therapeutics Market Size (US$ Mn) and Forecast, 2018–2027

    Figure 4: Global Gonorrhea Therapeutics Market Value Share, by Gonococcal Infection (2018)

    Figure 5: Global Gonorrhea Therapeutics Market Value Share, by Treatment (2018)

    Figure 6: Global Gonorrhea Therapeutics Market Value Share, by Route of Administration (2018)

    Figure 7: Global Gonorrhea Therapeutics Market Value Share, by Gender (2018)

    Figure 8: Global Gonorrhea Therapeutics Market Value Share, by Distribution Channel (2018)

    Figure 9: Global Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

    Figure 10: Global  Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Uncomplicated Gonococcal Infection, 2017–2027

    Figure 11: Global  Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Gonococcal Arthritis, 2017–2027

    Figure 12: Global  Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Gonococcal Meningitis and Endocarditis, 2017–2027

    Figure 13: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2019–2027

    Figure 14: Global Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 15: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Monotherapy, 2017–2027

    Figure 16: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Dual Therapy, 2017–2027

    Figure 17: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 18: Global Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

    Figure 19: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2027

    Figure 20: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Injectable 2017–2027

    Figure 21: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2019–2027

    Figure 22: Global Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

    Figure 23: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Women, 2017–2027

    Figure 24: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Men 2017–2027

    Figure 25: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2019–2027

    Figure 26: Global Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 27: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

    Figure 28: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

    Figure 29: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

    Figure 30: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

    Figure 31: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 32: Global Gonorrhea Therapeutics Market Value Share Analysis, by Region, 2018 and 2027

    Figure 33: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Region, 2019–2027

    Figure 34: North America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

    Figure 35: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027

    Figure 36: North America Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

    Figure 37: North America Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 38: North America Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

    Figure 39: North America Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

    Figure 40: North America Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 41: North America Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

    Figure 42: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

    Figure 43: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

    Figure 44: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

    Figure 45: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

    Figure 46: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

    Figure 47: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

    Figure 48: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027

    Figure 49: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

    Figure 50: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 51: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

    Figure 52: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

    Figure 53: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 54: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

    Figure 55: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

    Figure 56: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

    Figure 57: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

    Figure 58: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

    Figure 59: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

    Figure 60: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

    Figure 61: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027

    Figure 62: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

    Figure 63: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 64: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

    Figure 65: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

    Figure 66: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 67: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

    Figure 68: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

    Figure 69: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

    Figure 70: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

    Figure 71: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

    Figure 72: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

    Figure 73: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

    Figure 74: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027

    Figure 75: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

    Figure 76: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 77: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

    Figure 78: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

    Figure 79: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 80: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

    Figure 81: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

    Figure 82: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

    Figure 83: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

    Figure 84: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

    Figure 85: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

    Figure 86: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

    Figure 87: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2018–2027

    Figure 88: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

    Figure 89: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 90: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

    Figure 91: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

    Figure 92: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 93: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

    Figure 94: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

    Figure 95: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

    Figure 96: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

    Figure 97: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

    Figure 98: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

Copyright © Transparency Market Research, Inc. All Rights reserved